Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeOsteoRemedies® LLCOsteoRemedies® Announces the Full Commercial Launch of the First Preformed Knee Spacer with Modular Stems

OsteoRemedies® Announces the Full Commercial Launch of the First Preformed Knee Spacer with Modular Stems

OsteoRemedies® announced the full commercial launch of the REMEDY® Stemmed Knee Spacer at the 2019 American Association of Hip and Knee Surgeons (AAHKS) in Dallas, TX.  Building on its portfolio consisting of the only preformed modular spacer systems with Gentamicin for the hip, knee, and shoulder, as well as the only Gentamicin + Vancomycin preformed modular spacer and Bone Cement for the hip, the REMEDY® Stemmed Knee will provide surgeons with the first ever preformed knee spacer with attachable modular stems that can connect to the femoral and tibial component.

“Our vision is to continue to provide simple but comprehensive solutions to the growing clinical challenges surrounding infected total joints.  By providing surgeons with the only modular knee stems cleared by the FDA, we believe our portfolio remains the most robust which allows us to bolster our leadership position,” stated Chris Hughes, President and CEO, OsteoRemedies®.

Eric Stookey, COO, OsteoRemedies® noted, “After 5 years clinical experience with the current knee spacer design, our surgeon design team and users clearly identified the need for additional knee stem extensions for use in more complex two-stage revisions for infection.  By incorporating our proprietary premolded and modular approach to the knee stem design, we can offer surgeons the opportunity to improve OR efficiency vs handmade IM dowels.”

OsteoRemedies will be showcasing this unique new product along with the complete portfolio of revision/infection based products November 8 – 9 at booth #315.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy